心肌梗死后接受体外膜氧合治疗患者的生存预测
该单中心回顾性研究纳入2008年6月至2016年9月接受VA-ECMO支持的急性心肌梗死合并心源性休克成人患者61例,评估14个预设变量与院内生存的关联,并外部验证ENCOURAGE评分。37例(60.7%)成功脱离VA-ECMO,36例(59.0%)存活。年龄<65岁(OR 14.6,95%CI 2.5-84.0,P=0.003)、BMI<32 kg/m²(OR 5.5,95%CI 1.2-25.4,P=0.029)、INR<2(OR 7.3,95%CI 1.3-40.1,P=0.022)与生存显著相关;首次乳酸<3 mmol/L者生存无显著升高(OR 4.4,95%CI 0.6-32.6,P=0.147)。以INR>2替代凝血酶原活动度<50%的改良ENCOURAGE评分预测生存的C统计量为0.74(95%CI 0.61-0.87)。
要点
- 年龄<65岁与院内生存显著相关:OR 14.6(95%CI 2.5-84.0),P=0.003。
- BMI<32 kg/m²与院内生存显著相关:OR 5.5(95%CI 1.2-25.4),P=0.029。
- INR<2与院内生存显著相关:OR 7.3(95%CI 1.3-40.1),P=0.022。
- 首次乳酸<3 mmol/L者生存未见显著升高:OR 4.4(95%CI 0.6-32.6),P=0.147。
- 改良ENCOURAGE评分(以INR>2替代凝血酶原活动度<50%)预测生存C统计量0.74(95%CI 0.61-0.87)。
适用人群与场景
- 成人急性心肌梗死合并心源性休克并接受静脉-动脉体外膜氧合(VA-ECMO)支持的患者,时间范围为2008年6月至2016年9月。
研究设计与关键结果
- 研究类型为回顾性临床研究,单中心学术教学医院,样本量61例,主要终点为院内生存。
- 37例(60.7%)成功脱离VA-ECMO,36例(59.0%)存活。
- 年龄<65岁者生存显著更高:OR 14.6(95%CI 2.5-84.0),P=0.003。
- BMI<32 kg/m²者生存显著更高:OR 5.5(95%CI 1.2-25.4),P=0.029。
- INR<2者生存显著更高:OR 7.3(95%CI 1.3-40.1),P=0.022。
- 首次乳酸<3 mmol/L者生存无显著升高:OR 4.4(95%CI 0.6-32.6),P=0.147。
- 改良ENCOURAGE评分(以INR>2替代凝血酶原活动度<50%)预测生存的C统计量为0.74(95%CI 0.61-0.87)。
证据类型、等级与局限
- 证据类型:回顾性临床研究(单中心)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,年龄、BMI、INR等协变量与急性心肌梗死合并心源性休克接受VA-ECMO患者的生存相关,ENCOURAGE评分经外部验证可用于预测院内生存。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Acute myocardial infarction is the most common cause of cardiogenic shock. Although the number of patients with acute myocardial infarction complicated by cardiogenic shock who were treated with venoarterial extracorporeal membrane oxygenation increased during the last decade, detailed data on survival are lacking. We sought to analyze covariates that were independently associated with survival in this patient population and to externally validate the newly developed prEdictioN of Cardiogenic shock OUtcome foR Acute myocardial infarction patients salvaGed by venoarterial Extracorporeal membrane oxygenation (ENCOURAGE) score.
DESIGN: Retrospective clinical study.
SETTING: A single academic teaching hospital.
PATIENTS: Adult patients with acute myocardial infarction complicated by cardiogenic shock who were supported by venoarterial extracorporeal membrane oxygenation from June 2008 to September 2016.
INTERVENTIONS: Fourteen individual variables were assessed for their association with the primary endpoint. These variables were prespecified by the study team as being the most likely to affect survival. A receiver operating characteristic analysis was also performed to test the ability of the ENCOURAGE score to predict survival in this patient cohort.
MEASUREMENTS AND MAIN RESULTS: The primary endpoint of the study was in-hospital survival. A total of 61 patients were included in the analysis. Thirty-seven (60.7%) could be weaned from venoarterial extracorporeal membrane oxygenation and 36 (59.0%) survived. Survival was significantly higher in patients less than 65 years old (odds ratio, 14.6 [CI, 2.5-84.0]; p = 0.003), whose body mass index was less than 32 kg/m (odds ratio, 5.5 [CI, 1.2-25.4]; p = 0.029) and international normalized ratio was less than 2 (odds ratio, 7.3 [CI, 1.3-40.1]; p = 0.022). In patients where the first lactate drawn was less than 3 mmol/L, the survival was not significantly higher (odds ratio, 4.4 [CI, 0.6-32.6]; p = 0.147). The C-statistic for predicting survival using a modified version of the ENCOURAGE score, which replaced prothrombin activity less than 50% with an international normalized ratio greater than 2, was 0.74 (95% CI, 0.61-0.87).
CONCLUSIONS: In this single-center study, several important covariates were associated with improved survival in patients with acute myocardial infarction complicated by cardiogenic shock who were supported by venoarterial extracorporeal membrane oxygenation and the ENCOURAGE score was found to be externally valid for predicting survival to hospital discharge.
参考来源
- Pabst D, Foy AJ, Peterson B, et al. Predicting Survival in Patients Treated With Extracorporeal Membrane Oxygenation After Myocardial Infarction. Crit Care Med. 2018. PMID: 29373359. doi:10.1097/CCM.0000000000002995
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。